The estimated Net Worth of Mark J Ahn is at least $2.76 Million dollars as of 8 November 2016. Mark Ahn owns over 150,000 units of Abeona Therapeutics Inc stock worth over $2,756,887 and over the last 9 years Mark sold ABEO stock worth over $0.
Mark has made over 2 trades of the Abeona Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Mark exercised 150,000 units of ABEO stock worth $346,500 on 8 November 2016.
The largest trade Mark's ever made was exercising 150,000 units of Abeona Therapeutics Inc stock on 8 November 2016 worth over $346,500. On average, Mark trades about 42,046 units every 117 days since 2015. As of 8 November 2016 Mark still owns at least 493,182 units of Abeona Therapeutics Inc stock.
You can see the complete history of Mark Ahn stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is 3333 Lee Pkwy #600, Dallas, TX 75219, USA.
Over the last 15 years, insiders at Abeona Therapeutics Inc have traded over $4,486,735 worth of Abeona Therapeutics Inc stock and bought 427,809 units worth $1,765,143 . The most active insiders traders include Capital Partners Llc Rouhan..., Todd Wider, and Michael Amoroso. On average, Abeona Therapeutics Inc executives and independent directors trade stock every 50 days with the average trade being worth of $256,542. The most recent stock trade was executed by Mark Alvino on 17 June 2024, trading 25,890 units of ABEO stock currently worth $116,764.
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Abeona Therapeutics Inc executives and other stock owners filed with the SEC include: